Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration

Macular Degeneration, Dry Clinical Trial

— PASCAL-RPD  

Official title:

Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04847635
• Other study ID #: PASCAL-RPD
• Status: Recruiting
• Phase: N/A
• Start date: March 16, 2021
• Est. completion date: September 1, 2024

Study information

• Verified date: August 2023
• Source: Ospedale San Raffaele
• Contact: Giuseppe Querques, MD, PhD
• Phone: +390226434004
• Email: querques.giuseppe[@]hsr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD.

The objective of this study is to establish the effectiveness of subthreshold laser treatment in increase/prevent the decrease of the retinal sensibility in patients with reticular pseudodrusen, and to reduce the progression of RPD to atrophy.

Approximately 50 naïve patients with reticular pseudodrusen who underwent subthreshold laser treatment in perifoveal area. These patients should be randomized in the 2 study arms of the study. Patients will be evaluated at Screening/Baseline and then revaluated and retreated at month 3, 6 and 9. At month 12, all patients will be evaluated with a full ocular examination, visual acuity measurement (VA), optical coherence tomography (OCT) with autofluorescence, OCT-angiography and microperimetry.

The rationale of the study is to prevent the evolution of reticular pseudodrusen to atrophic degeneration.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: September 1, 2024
• Est. primary completion date: September 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• 50 years or older

• Presence of RPD secondary to AMD

• Best-corrected visual acuity (BCVA) between 20/20 and 20/400 inclusive

• Clear ocular media

• Ability to provide informed consent and attend all study visits

Exclusion Criteria:

• Presence of Geographic Atrophy (GA)

• Evidence of choroidal neovascularization in either eye

• Any prior treatment for AMD, aside from antioxidants

• Any corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures

• Aphakic eye with vitreous in the anterior chamber

• Neovascular Glaucoma

• Glaucoma caused by congenital angle anomalies

• Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner

• Significant corneal edema or reduced water clarity that obscures the view angle in detail

• Glaucoma secondary to active uveitis

• Any other ocular condition that would progress in the study period and confound visual acuity assessment

• Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve Presence of idiopathic or autoimmune-associated uveitis

• Any intraocular surgery 3 months of entry

• Any prior thermal laser in the macula

• History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery

• Previous therapeutic radiation in the ocular region in either eye

• Any treatment with an investigational agent in the previous 60 days before study entry

• Women of child-bearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization (further definition can be found in Section 12.7) at Baseline, unless they are using highly effective methods of contraception during dosing of study treatment.

• Participation in an investigational drug, biologic, or device study within 6 Months prior to Baseline [Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary

Related Conditions & MeSH terms

• Geographic Atrophy
• Laser Burn of Retina
• Macular Degeneration
• Macular Degeneration Intermediate
• Macular Degeneration, Dry
• Macular Degeneration, Senile

Intervention

Device:
• Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area.
• Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)
The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.

Locations

Country	Name	City	State
Italy	Massimo Nicolò	Genova
Italy	Giuseppe Querques	Milan
Italy	Mariacristina Parravano	Rome

Sponsors (4)

Lead Sponsor	Collaborator
Ospedale San Raffaele	Fondazione G.B. Bietti, IRCCS, University of Genova, University of Rome Tor Vergata

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Querques G, Sacconi R, Gelormini F, Borrelli E, Prascina F, Zucchiatti I, Querques L, Bandello F. Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration. Sci Rep. 2021 Jan 26;11(1):2193. doi: 10.1038/s41598-021-81810-7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in the retinal sensitivity - 12 months	Functional changes in the retinal sensitivity on customized microperimetry from day 0 to month 12 (unit of measure: dB)	12 months
Primary	Anatomical changes using structural optical coherence tomography (OCT)	Anatomical changes will be evaluated with retinal thickness (unit of measure: microns)	12 months
Primary	Rate of Progression	Rate of progression to advance AMD (GA and/or neovascular AMD)	12 months
Secondary	Changes in the retinal sensitivity - 6 months	Functional changes in the retinal sensitivity on customized microperimetry from day 0 to month 6 (unit of measure: dB)	6 months
Secondary	Anatomical changes using fundus autofluorescence (FAF)	Anatomical changes will be evaluated analyzing the development of geographic atrophy using FAF	12 months
Secondary	Genetic influence (% of AMD-associated single-nucleotide polymorphism (SNP) in treated patients)	The % of AMD-associated single-nucleotide polymorphism (SNP) will be evaluated analyzing the % of patients with an AMD-associated SNP in patients showing no progression vs progression to advance AMD (main outcome 3).	12 months
Secondary	Anatomical changes using OCT-angiography (OCT-A)	Anatomical changes will be evaluated analyzing the perfusion density by means of OCT-A	12 months